CRVS peer analysis
Corvus Pharmaceuticals (CRVS) against its competitors: price, today's move, 1-year return and market value side by side.
CRVS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADAG Adagene | $2.35 | 2.62% | 31.28% | – |
| CGEN Compugen | $2.01 | 1.52% | 16.18% | $190.40M |
| CHRS Coherus Oncology | $0.85 | 5.88% | -46.69% | $124.47M |
| CMPX Compass Therapeutics | $0.77 | 1.99% | -79.47% | – |
| CTMX CytomX Therapeutics | $2.35 | 7.80% | -40.20% | $475.02M |
| IPHA Innate Pharma | $1.33 | -5.00% | -36.36% | $148.56M |
| MGNX MacroGenics | $2.31 | -0.86% | 46.20% | $148.42M |
| NKTR Nektar | $38.20 | 1.17% | -36.25% | $1.29B |
| NXTC NextCure | $5.91 | 3.78% | -53.10% | $27.05M |
| RCUS Arcus Biosciences | $19.36 | 2.38% | -4.86% | $2.41B |
| CRVS Corvus Pharmaceuticals | $10.58 | 7.63% | 37.76% | $826.91M |
- CRVS's peers: ADAG (Adagene), CGEN (Compugen), CHRS (Coherus Oncology), CMPX (Compass Therapeutics), CTMX (CytomX Therapeutics), IPHA (Innate Pharma), MGNX (MacroGenics), NKTR (Nektar).
Updated 2026-11-05 12:50 UTC